Cancer Institute of NJ Adds to its Staff
NEW BRUNSWICK, NJ--Last month, The Cancer Institute of New Jersey welcomed Joseph Aisner, MD, as its new associate director of clinical science, and added four new physician/scientists to its staff.
NEW BRUNSWICK, NJ--Last month, The Cancer Institute of New Jerseywelcomed Joseph Aisner, MD, as its new associate director of clinicalscience, and added four new physician/scientists to its staff.
Dr. Aisner will also serve as chief of the Division of MedicalOncology and professor of medicine and environment and communitymedicine. He was recruited from the University of Maryland wherehe was chief of medical oncology and director of the Cancer Center.
Joseph Germino, MD, and Eric H. Rubin, MD, have joined the Instituteas assistant professors of medicine. Dr. Germino comes from YaleUniversity School of Medicine and Dr. Rubin from Dana-Farber andHarvard Medical School.
James Stephen Goydos, MD, of the University of Pittsburgh, isa new instructor of surgery, and Thomas Joseph Kearney, MD, ofthe University of Chicago, is assistant professor of surgery.
Established in 1990, The Cancer Institute of New Jersey is a partnershipof four New Jersey hospitals and medical centers, the Universityof Medicine and Dentistry of New Jersey (UMDNJ), and the UMDNJ-RobertWood Johnson Medical School.
![We have the current CAR [T-cell therapies], which target CD19; however, we need others.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6d5ddb2c2098f525a65b378ece6ca55a114f95fc-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "We have the current CAR [T-cell therapies], which target CD19; however, we need others.")
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
